Caribou Biosciences Cuts Workforce, Shifts Pipeline to Focus on Key Oncology Programs

Dow Jones

04-25

By Kelly Cloonan

Caribou Biosciences plans to trim its workforce and shift its pipeline as it looks to focus on its lead oncology programs.

The Berkeley, Calif.-biopharmaceutical company on Thursday said it plans to reduce its workforce by about 32%. Such cuts would amount to roughly 47 employees, based on the total workforce of 147 full-time employees according to its latest annual filing.

The company is also discontinuing preclinical research as well as Phase 1 trials of treatments for lupus and relapsed or refractory acute myeloid leukemia.

Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million.

The changes will extend Caribou's cash runway by one year, funding the current operating plan into the second half of 2027, it said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

April 24, 2025 17:08 ET (21:08 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2530539999"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2530539999\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2530539999?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-25 05:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2530539999","market":"sg","top_or_hot":-1,"title":"Caribou Biosciences Cuts Workforce, Shifts Pipeline to Focus on Key Oncology Programs","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CRBU\">Caribou Biosciences</a> plans to trim its workforce and shift its pipeline as it looks to focus on its lead oncology programs. \n</p>\n<p>\n  The Berkeley, Calif.-biopharmaceutical company on Thursday said it plans to reduce its workforce by about 32%. Such cuts would amount to roughly 47 employees, based on the total workforce of 147 full-time employees according to its latest annual filing. \n</p>\n<p>\n  The company is also discontinuing preclinical research as well as Phase 1 trials of treatments for lupus and relapsed or refractory acute myeloid leukemia. \n</p>\n<p>\n  Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million. \n</p>\n<p>\n  The changes will extend Caribou's cash runway by one year, funding the  current operating plan into the second half of 2027, it said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 24, 2025 17:08 ET (21:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Caribou Biosciences Cuts Workforce, Shifts Pipeline to Focus on Key Oncology Programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCaribou Biosciences Cuts Workforce, Shifts Pipeline to Focus on Key Oncology Programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-25 05:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CRBU\">Caribou Biosciences</a> plans to trim its workforce and shift its pipeline as it looks to focus on its lead oncology programs. \n</p>\n<p>\n  The Berkeley, Calif.-biopharmaceutical company on Thursday said it plans to reduce its workforce by about 32%. Such cuts would amount to roughly 47 employees, based on the total workforce of 147 full-time employees according to its latest annual filing. \n</p>\n<p>\n  The company is also discontinuing preclinical research as well as Phase 1 trials of treatments for lupus and relapsed or refractory acute myeloid leukemia. \n</p>\n<p>\n  Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million. \n</p>\n<p>\n  The changes will extend Caribou's cash runway by one year, funding the  current operating plan into the second half of 2027, it said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 24, 2025 17:08 ET (21:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRBU","symbol_name":"Caribou Biosciences","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2530539999","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2530539999","pubTimestamp":1745528880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Caribou Biosciences plans to trim its workforce and shift its pipeline as it looks to focus on its lead oncology programs.The Berkeley, Calif.-biopharmaceutical company on Thursday said it plans to reduce its workforce by about 32%. Such cuts would amount to roughly 47 employees, based on the total workforce of 147 full-time employees according to its latest annual filing.The company is also discontinuing preclinical research as well as Phase 1 trials of treatments for lupus and relapsed or refractory acute myeloid leukemia.Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million.The changes will extend Caribou's cash runway by one year, funding the  current operating plan into the second half of 2027, it said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRBU":"Caribou Biosciences","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"Caribou Biosciences裁员，将产品线转移到关键肿瘤学项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRBU":1},"content_text":"By Kelly Cloonan \n\n\n \n\n\nCaribou Biosciences plans to trim its workforce and shift its pipeline as it looks to focus on its lead oncology programs. \n\n\n  The Berkeley, Calif.-biopharmaceutical company on Thursday said it plans to reduce its workforce by about 32%. Such cuts would amount to roughly 47 employees, based on the total workforce of 147 full-time employees according to its latest annual filing. \n\n\n  The company is also discontinuing preclinical research as well as Phase 1 trials of treatments for lupus and relapsed or refractory acute myeloid leukemia. \n\n\n  Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million. \n\n\n  The changes will extend Caribou's cash runway by one year, funding the  current operating plan into the second half of 2027, it said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 24, 2025 17:08 ET (21:08 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}